TTI-101 IV / Tvardi Therap - LARVOL DELTA

New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC) (Yahoo Finance) - "TTI-101 achieved approximately 8-fold higher drug levels in the colon than in plasma, indicating accumulation in the target organ, at pharmacologically relevant levels for inhibition of STAT3-dependent proliferation...TTI-101 reversed many disease-induced changes in colon gene expression, including genes associated with colorectal cancer and STAT3 signaling....TTI-101 prevented adenocarcinoma formation entirely (p≤0.05), while pY-STAT3 (activated STAT3) was found to be elevated in the tumors that developed in vehicle-treated animals. TTI-101 reached levels more than 20 times the STAT3 IC50 (the concentration needed to block STAT3-driven growth) in the colon."

Preclinical • Ulcerative Colitis